***Introduction.*** The authors of these bulletins are infectious diseases physicians on the front line in the epidemic of severe acute respiratory syndrome (SARS) in Hong Kong. They are affiliated with the Division of Infectious Disease, Department of Microbiology, at Queen Mary Hospital and the University of Hong Kong, and they are also caring for patients in the Pamela Youde Nethersole Eastern Hospital, Princess Margaret Hospital, and Kwong Wah Hospital. Their bulletins are being published in the News section of the electronic edition of *Clinical Infectious Diseases* within 1--2 days after receipt in our office; below is a condensation of the bulletins for 6--13 April 2003.---*Sherwood Gorbach*

***Bulletin.*** Within a week, \>200 residents of the Amoy Garden housing development in Hong Kong came down with SARS. During the initial outbreak, we saw 70 of these patients. Many of them were young and otherwise healthy, and this subgroup tended to have a more complicated clinical course of SARS and required more frequent pulse methylpredisolone therapy than did patients with SARS whom we saw at other regional hospitals. It is suspected that some of them had been exposed to high doses of virus at the time of contact. The mode of transmission may not be simply person-to-person contact; environmental factors may play an important role. However, so far, we have no evidence that rodents or fomites played a part in transmission.

There is a debate among clinicians about how to treat SARS-infected pregnant women. We have seen numerous viral particles in type II pneumatocytes and highly activated macrophages in lung tissue specimens of from patients who have died of the disease without having received treatment with ribavirin and steroids. We know that, at the dosage given intravenously, ribavirin has a modest level of activity against the coronavirus that causes SARS. The final consensus is that, because of potential teratogenicity, we should avoid giving ribavirin to pregnant women at \<13 weeks\' gestation or should offer abortion to such women who want to receive treatment with ribavirin and steroids. Despite reports of pregnant women who have taken ribavirin and delivered healthy babies, studies of rats have clearly demonstrated the teratogenic effects of prolonged and high-dose ingestion.

There is also a debate about whether to administer oral ribavirin prophylaxis to health care workers who have been exposed to patients with coronavirus pneumonia. Opponents argue that the oral formulation can never achieve inhibitory concentrations and may cause hemolysis and even cardiac arrhythmia. Proponents believe that it may be as effective as is oral acyclovir prophylaxis against cytomegalovirus disease in recipients of kidney and bone-marrow transplants. However, cardiac complications are rare, and the duration of prophylaxis is only 2 weeks. In the end, no consensus was reached.

With unknown and serious infections, controversy always arises because of the lack of randomized, placebo-controlled studies. In the case of SARS, treatment with intravenously administered ribavirin and steroids is seriously questioned. In vitro susceptibility testing has shown that ribavirin\'s inhibitory concentration against the coronavirus is ∼30 μg/mL, which is much higher than the usual 1--5 μg/mL for the causative agents of other respiratory diseases.

The conditions of ∼10% of our patients continued to deteriorate despite administration of ribavirin and steroid therapy, and treatment with serum therapy was considered. Patients recovering from infection were asked to provide convalescent-phase plasma specimens by plasmapheresis. Generally, health care workers were willing to donate plasma, whereas other patients were reluctant because they had had a bad experience with SARS and were also at risk of being infected with a different strain of coronavirus and of the hazards associated with human blood products. Patients who agreed to donate plasma were tested to confirm that they had normal liver function and were not infected with other pathogens, including this novel coronavirus. Approximately 500 mL of a convalescent-phase plasma specimen with high antibody titer was given to each of the patients whose conditions had not responded to ribavirin and steroid therapy. However, too few patients have been treated with passive immunization to allow us to draw any conclusions about its efficacy.

It is important to know that the presence of a neutralizing antibody against the known coronaviruses that cause the common cold does not protect against reinfection with the same strain of coronavirus. Of the 200 healthy blood donors who were screened, none had an antibody titer of \>1:10 against this novel coronavirus. Other treatments, such as plasmaphere-sis, intravenous immunoglobulin, and pen-ta-globulin, have been tried by clinicians at other hospitals, but no randomized, controlled studies have been possible. At the moment, we do not have a strong feeling that these modalities are working.---*V. C. C. Cheng, M. Peiris, and K. Y. Yuen*
